An investigation into B12 absorption in diabetic patients on long-term phenformin therapy was undertaken and the results were compared to a similar investigation previously reported in diabetics on long-term metformin.
Introduction
The biguanide hypoglycaemic agents metformin and phenformin are known to interfere with absorption (Czyzyk et al., 1968) . Carbohydrate malabsorption is probably beneficial to maturity onset diabetes in obese subjects and the hypoglycaemic effect of the drugs may be in part related to their effect on absorption. A detrimental effect of metformin was the finding of vitamin B12 malabsorption in 30% of patients on long-term metformin therapy (Tomkin et al., 1971 ). Phenformin has not been shown to cause B12 malabsorption in acute short-term experiments (Willms and Creutzfeldt, 1970) but it seemed important to verify this in patients on long-term therapy.
This paper reports an investigation of B12 absorption in diabetic patients on long-term phenformin therapy and compares the results with the previously reported study of patients on long-term metformin therapy (Tomkin et al., 1971) . Subjects and Methods Twenty-four unselected patients with maturity onset diabetes who had been on phenformin for at least three years and were attending the Cincinnati General Hospital Diabetic Clinic were investigated. The mean age of these patients was 54 years (S.E. of mean ± 2-1). They had been on 102-4 ± 6-4 mg of phenformin for 4-8 ± 0 5 years (mean + S.E. of mean). Eleven subjects who did not have diabetes or malabsorption, and who had normal renal function, acted as controls. A Schilling test was performed on all subjects using 58Co B12 with intrinsic factor. Urine was collected for 48 hours in two 24-hour aliquots. Serum B12 and folic acid estimations were carried out in Belfast as previously described (Tomkin et al., 1971) The mean age of group 1 was 54-1 ± 2X9 years (table I). This was not significantly different from group 2 whose mean age was 55-7 ± 2-6 (P> 0.05). The mean dose of phenformin in group 1 was 104-5 ± 10-6 mg/day and in group 2 was 100 0 ± 7-4 mg/day (P> 0.05). There was no difference between the duration of therapy in the two groups (group 1 = 4-6 0 5 years, group 2 = 5.3 ± 0-8 years; P > 0 05). The mean haemoglobin level in group 1 was 13-4 ± 0 37 g/100 ml. This was not significantly different from group 2 (13-6 ± 0-26 g/100 ml, P> 0-05). None of the patients were anaemic (Hb < 13-5 g/100 ml in men and <11-5 g/100 ml in women). The mean serum B12 level in group 1 was 655-3 82-3 pg/ml, and in group 2 was 640-1 ± 24-9 pg/ml (P > 0.05). Serum folic acid in group 1 was 6-6 ± 1-4 ng/ml, and in group 2 was 5-1 1-0 ng/ml. Again this difference was not significant (P > 0.05). Blood urea nitrogen (normal 10-20 mg/100 ml) was 16-1 ± 2-3 mg/100 ml in group 1 and 17-8 ± 2-6 mg/100 ml in group 2. The difference was not significant (P > 0.05). COMPARISON WITH 1971 srUDy The mean age of the patients on metformin was 62-2 ± 1 2 years (table II) . They were significantly older than the patients on phenformin whose mean age was 53 9 ± 2-1 years (t = 3-1, P < 0-01). The incidence of low results of Schilling tests in this study was 46% as compared to 30% in the metformin study.
This difference was not significant (X2 = 146, P > 0 05). The mean duration of therapy of the phenformin patients was 4-8 ± 0 5 years as compared to a mean of 4-7 ± 0-4 years for the metformin patients. The mean 24-hour B12 excretion during the Schilling test was 4-8 ± 0-5% in the metformin patients with abnormal results. This was very similar to the mean of group 2 patients on phenformin. The mean B12 level in all the P>005 patients investigated on metformin was 495 7 ± 28-9 pg/ml, which was lower than the mean B12 level of groups 1 and 2 on phenformin, which was 6360 ± 39-25 pg/ml. The mean serum B12 in the metformin patients with B12 malabsorption was 381-2 + 57.5 pg/ml. This was much lower than the mean level in group 2 on phenformin which was 64041 + 24-9 pg/ml.
Mean serum folic acid in all the patients investigated on metformin was 7 9 ± 06 ng/ml. This was similar to the mean level of groups 1 and 2 (mean 6-8 ± 07 ng/ml). The mean serum folic acid was 9-6 ± 1-6 ng/ml in the metformin patients with B12 malabsorption. This was higher than the level found in group 2, which was 5-1 ± 1.0 ng/ml.
Discussion
The mode of action of the biguanides in lowering the blood sugar in mild diabetic patients is uncertain but it has been shown that these drugs inhibit the absorption of glucose (Czyzyk et al., 1968; Hollobaugh et al., 1970) and in vitro experiments have shown the impairment of the active absorption of glucose (Kruger et al., 1970) . Vitamin B12 is another substance that is absorbed by active transport from the small bowel (distal ileum), and it has been shown that metformin interferes with the absorption of B12 (Berchtold et al., 1969; Willms and Creutzfeldt, 1970; Tomkin et al., 1971) . The effect of phenformin on B12 absorption has been studied only in patients taking the drug for short periods (Willms and Creutzfeldt, 1970) , when no abnormality of B12 absorption was found. This study has shown that almost half (46%) of the patients examined had B12 malabsorption as shown by pathologically low excretion of GoCo B12 in the urine. The Schilling test depends on the absorption of the labelled vitamin from the distal ileum and the renal clearance of the vitamin. Delay in the absorption of the vitamin during the test might be due to delay in gastric emptying which is known to occur in a proportion of diabetics (Tomkin, 1973) , but if this was so it would be expected that the second 24-hour urine collection would contain a higher percentage of the vitamin than the controls. This was not found. The second 24-hour excretion in group 2 was 3-9% as compared with 6-5% in group 3. A second possibility is that the renal clearance of the labelled vitamin might have been impaired in group 2. This is also unlikely as the blood urea nitrogen levels were normal and not significantly different from group 1 (P > 0 05). Ifthere was a delay in renal clearance then the second 24-hour value might be expected to be greater than that of group 3, but this was not the case. Finally, in our previous study a control group of 19 diabetics on long-term chlorpropamide therapy had normal results of Schilling tests, which suggests that it is rare for a diabetic with a normal blood urea to have an abnormal test result unless they are on metformin or phenformin therapy.
The abnormality in the result of the Schilling test appears reproducible as only one out of five patients retested had improved the percentage 58Co B12 excretion in the urine, and even then the result was only borderline normal ( fig. 2) . That the phenformin was responsible for the abnormal results is suggested by the normal repeat tests in the four patients from group 2 after the drug was discontinued (fig. 3) . The group of patients on metformin previously studied were on average eight years older but the duration of therapy was similar as was the depression in B12 excretion. The effect of malabsorption of B12 in group 2 was not apparent as no patient was found to be anaemic or B12 deficient and B12 levels were not significantly different from group 1 (P > 0 05). As only 24 patients on phenformin were examined this is not significantly different from the findings in the metformin study. Only four patients out of 71 were discovered with evidence of B12 deficiency in the metformin study (P = 0 57). Twenty-one of these patients had low Schilling test results and the four patients discovered with low B12 levels all had low results. Only 11 patients in group 2 had low results and again the finding of no abnormal B12 level in this small sample was not significantly different from the findings in the metformin study (P = 0 29).
The higher mean B12 levels in groups 1 and 2 when compared to the mean level of the metformin patients (table II) suggests that the inhibition of B12 absorption may be less severe in patients on phenformin. This is further supported by the lower serum folic acid levels in group 2 when compared to the patients with B12 malabsorption on metformin, because some of the highest levels of serum folic acid are found in patients with pernicious anaemia (Herbert et al., 1960; Waters and Mollin, 1961) . Therefore, an inverse relation between serum Bl2 and folic acid might be expected.
The higher mean serum B12 in group 2 may be explained by the concentration of biguanide in the intestinal lumen, as the therapeutic dose of metformin is about 10 times that of phenformin. Alternatively, the difference may be due to the difference in the metabolism of the two drugs, metformin being excreted unchanged in the urine (Beckmann, 1969) , whereas about one-third of phenformin is metabolized to hydroxyphenethyl biguanide (Beckmann, 1968) . Clarification of the mechanism of B12 malabsorption may come when it is known whether the effect is a local one on mucosa of the distal ileum or whether prior absorption of the drug is necessary. It seems unlikely that a genetic difference in the handling of the biguanides could account for the high incidence of B12 malabsorption, as a unimodal distribution of results of 24-hour Schilling tests was found in the combined metformin and phenformin patients.
Partial gastric resection is known to cause B12 malabsorption but the discovery of vitamin B12 deficiency may take from 12 to 15 years (Deller and Witts, 1962; Weir et al., 1963) . It is therefore concluded that though no patient in this study was shown to have B12 deficiency, in view of the high proportion of abnormal results of Schilling tests, serum B12 levels should be estimated annually in all patients on long-term phenformin or metformin therapy. 
